Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

Karl L Banta,Xiaozheng Xu,Avantika S Chitre,Amelia Au-Yeung,Chikara Takahashi,William E O'Gorman,Thomas D Wu,Stephanie Mittman,Rafael Cubas,Laetitia Comps-Agrar,Amit Fulzele,Eric J Bennett,Jane L Grogan,Enfu Hui,Eugene Y Chiang,Ira Mellman,Karl L. Banta,Avantika S. Chitre,William E. O’Gorman,Thomas D. Wu,Eric J. Bennett,Jane L. Grogan,Eugene Y. Chiang

DOI: https://doi.org/10.1016/j.immuni.2022.02.005

IF: 32.4

2022-03-01

Immunity

Abstract:Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT blockade modulate anti-tumor CD8+ T cells. Although PD-1 and TIGIT are thought to regulate different costimulatory receptors (CD28 and CD226), effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226. CD226 expression associated with clinical benefit in patients with non-small cell lung carcinoma (NSCLC) treated with anti-PD-L1 antibody atezolizumab. CD226 and CD28 were co-expressed on NSCLC infiltrating CD8+ T cells poised for expansion. Mechanistically, PD-1 inhibited phosphorylation of both CD226 and CD28 via its ITIM-containing intracellular domain (ICD); TIGIT's ICD was dispensable, with TIGIT restricting CD226 co-stimulation by blocking interaction with their common ligand PVR (CD155). Thus, full restoration of CD226 signaling, and optimal anti-tumor CD8+ T cell responses, requires blockade of TIGIT and PD-1, providing a mechanistic rationale for combinatorial targeting in the clinic.

immunology